---
url: https://www.sec.gov/Archives/edgar/data/1611115/000119312525116907/d785770ds1.htm?utm_source=secondopinion.media&amp;utm_medium=newsletter&amp;utm_campaign=omg-omada-health-just-filed-its-s1&amp;_bhlid=7c574945aca46c87d3519a596dbac26c309a989b
title: "S-1"
clipped: 2025-12-23 13:04
source: slack
slack_channel: mkt-research-headlines
---

# S-1

> Source: [https://www.sec.gov/Archives/edgar/data/1611115/000119312525116907/d785770ds1.htm?utm_source=secondopinion.media&amp;utm_medium=newsletter&amp;utm_campaign=omg-omada-health-just-filed-its-s1&amp;_bhlid=7c574945aca46c87d3519a596dbac26c309a989b](https://www.sec.gov/Archives/edgar/data/1611115/000119312525116907/d785770ds1.htm?utm_source=secondopinion.media&amp;utm_medium=newsletter&amp;utm_campaign=omg-omada-health-just-filed-its-s1&amp;_bhlid=7c574945aca46c87d3519a596dbac26c309a989b)

##### [Table of Contents](#toc)

**As filed with the U.S. Securities and Exchange Commission on May 9, 2025.**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT**

***UNDER***

***THE
SECURITIES ACT OF 1933***

**Omada Health, Inc.**

**(Exact
name of registrant as specified in its charter)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Delaware** |  | **8000** |  | **45-2355015** |
| **(State or other jurisdiction of**  **incorporation or organization)** |  | **(Primary Standard Industrial**  **Classification Code Number)** |  | **(I.R.S. Employer**  **Identification Number)** |

**500 Sansome Street, Suite 200**

**San Francisco, California 94111**

**(888) 987-8337**

**(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)**

**Sean Duffy**

**Chief Executive
Officer**

**Omada Health, Inc.**

**500 Sansome Street, Suite 200**

**San Francisco, California 94111**

**(888) 987-8337**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

***Copies to:***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Kathleen M. Wells**  **Richard Kim**  **Latham & Watkins LLP**  **140 Scott Drive**  **Menlo Park, California 94025**  **(650) 328-4600** |  | **Nathan Salha**  **Omada Health, Inc.**  **500 Sansome Street, Suite 200**  **San Francisco, California 94111**  **(888) 987-8337** |  | **Alan F. Denenberg**  **Emily Roberts**  **Davis Polk & Wardwell LLP**  **900 Middlefield Road**  **Redwood City, California 94063**  **(650) 752-2000** |

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date of this
Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis
pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large
accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
| Large accelerated filer |  | ☐ |  | Accelerated filer |  | ☐ |
|  |  | |  | |  | |
| Non-accelerated filer |  | ☒ |  | Smaller reporting company |  | ☐ |
|  |  | |  | |  | |
|  |  |  |  | Emerging growth company |  | ☒ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration
statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.**

---

##### [Table of Contents](#toc)

![LOGO](g785770g82f58.jpg)

The information in this prospectus is not complete
and may be changed. We may not sell these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. PRELIMINARY PROSPECTUS (Subject to Completion) Issued , 2025 Shares omada Common Stock OMADA HEALTH, INC. is offering shares of its common stock. This is
our initial public offering, and no public market exists for our common stock. We anticipate that the initial public offering price will be between $ and $ per share. We have applied to list our common stock on the Nasdaq Global Market under the
trading symbol "OMDA". We are an "emerging growth company" as defined under the U.S. federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements in this prospectus and may elect to do so in
future filings. PRICE $ A SHARE Price to Public Underwriting Discounts and Commissions(1) Proceeds to Company Per share $ $ $ Total $ $ $ (1) See the section titled "Underwriters" beginning on page 237 for additional information regarding
compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of our common stock at the initial public offering price, less the underwriting discounts and
commissions. Investing in our common stock involves a high degree of risk. See the section titled "Risk Factors" beginning on page 18 to read about factors you should consider before buying shares of our common stock. Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to
deliver the shares of common stock to purchasers on , 2025. Morgan Stanley Goldman Sachs & Co. LLC J.P. Morgan , 2025

---

##### [Table of Contents](#toc)

![LOGO](g785770g48m63.jpg)

Our Mission Bend the curve of obesity of prediabetes of hypertension of diabetes of musculoskeletal disease

---

##### [Table of Contents](#toc)

![LOGO](g785770g91a01.jpg)

"When you see the results, like whether youre losing weight or your sugars are keeping level, it feels good, because you
know youre doing something right. It has enabled me to be accountable to myself and to implement what Ive learned. Knowing and actually really doing it is two different things. They provide the references and tools that you need to succeed to be a
healthier you." Anthony, Omada member, speaking about his experience with Omada Image features actual Omada member. Testimonial is based on the individuals real experience and results. We do not claim these are typical results that members will
achieve. Results may vary. This testimonial was gathered as part of user research for ongoing product development. The member was compensated for time spent in providing the feedback, which was written by the member and not Omada.

---

##### [Table of Contents](#toc)

![LOGO](g785770g40f88.jpg)

738B Steps counted 20M+ Benefit-covered individuals 2,000+ Customers 90% Customer retention 1M Members Enrolled Images,
including apps, do not reflect real members or information about a specific person unless otherwise stated. All data as of March 31, 2025, except for steps counted, which is as of December 31, 2024, customer retention, which is an average for the
year ended December 31, 2024, and benefit-covered individuals, which is estimated as of December 31, 2024. Benefit-covered individuals must also have a clinical need to enroll.

---

##### [Table of Contents](#toc)

![LOGO](g785770g33m01.jpg)

149M Meals tracked 78M Blood glucose readings 902K Meals with kale 9.7M Pounds lost 5.4M "Thank you"s All data from
inception to December 31, 2024.

---

##### [Table of Contents](#toc)

![LOGO](g785770g01a09.jpg)

A member journey that builds confidence and structure for long-term, sustained behavior change. Email introduction to
Omada from work Apply Receive acceptance notification PROGRAM START Receive welcome kit Meet the coach via welcome video Start messaging with dedicated coach Start using new connected devices Join a group of member peers Track steps & meals
Complete the first SMART goal Sign up for first charity walk Get advice from specialist on readings Add Breakfast Add Lunch Add Dinner Data auto syncs to members account Glucose Day Week Mo Today CGM + BGM Readings 198 mg/dl 300 250 200 150 100 50 0
12a 3 6 9 12p 3 6 9 12a Todays Notes 2:30 198 mg/dl CGM 2 slices of pepperoni pizza for lunch today. I usually have 3 so View all notes Glucose Levels & Color Code

---

##### [Table of Contents](#toc)

![LOGO](g785770g90a02.jpg)

Our Vision To deliver unrivaled virtual care between doctors visits through a simple, elegant, and seamless experience
for both members and buyers. Improve hemoglobin A1C levels Primary care provider ("PCP") check-up Stop 2 medications after PCP approves Care team & member celebrate progress

---

##### [Table of Contents](#toc)

**TABLE OF CONTENTS**

**PROSPECTUS**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  | **Page** | |  |
| [Glossary](#toc785770_00a) |  |  | i |  |
| [An Introduction From Our Co-Founder and CEO](#toc785770_1) |  |  | v |  |
| [Prospectus Summary](#toc785770_2) |  |  | 1 |  |
| [The Offering](#toc785770_3) |  |  | 12 |  |
| [Summary Consolidated Financial Data](#toc785770_4) |  |  | 14 |  |
| [Risk Factors](#toc785770_5) |  |  | 18 |  |
| [Special Note Regarding Forward-Looking Statements](#toc785770_6) |  |  | 76 |  |
| [Market and Industry Data](#toc785770_7) |  |  | 79 |  |
| [Use of Proceeds](#toc785770_8) |  |  | 82 |  |
| [Dividend Policy](#toc785770_9) |  |  | 83 |  |
| [Capitalization](#toc785770_10) |  |  | 84 |  |
| [Dilution](#toc785770_11) |  |  | 86 |  |
| [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#toc785770_12) |  |  | 89 |  |
| [Business](#toc785770_13) |  |  | 126 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  | **Page** | |  |
| [Management](#toc785770_14) |  |  | 191 |  |
| [Executive and Director Compensation](#toc785770_15) |  |  | 200 |  |
| [Certain Relationships and Related-Party Transactions](#toc785770_16) |  |  | 214 |  |
| [Principal Stockholders](#toc785770_17) |  |  | 218 |  |
| [Description of Capital Stock](#toc785770_18) |  |  | 221 |  |
| [Shares Eligible for Future Sale](#toc785770_19) |  |  | 229 |  |
| [Material U.S. Federal Income Tax Consequences to Non-U.S. Holders](#toc785770_20) |  |  | 233 |  |
| [Underwriters](#toc785770_21) |  |  | 237 |  |
| [Legal Matters](#toc785770_22) |  |  | 250 |  |
| [Experts](#toc785770_23) |  |  | 250 |  |
| [Change in Independent Registered Public Accounting Firm](#toc785770_24) |  |  | 250 |  |
| [Where You Can Find Additional Information](#toc785770_25) |  |  | 251 |  |
| [Index to Consolidated Financial Statements](#toc785770_26) |  |  | F-1 |  |

As used in this prospectus, unless the context otherwise requires, references to “Omada,” “Omada Health,”
the “company,” “we,” “us,” and “our” refer to Omada Health, Inc. and, where appropriate, its subsidiary and consolidated professional corporation, taken as a whole.

“Omada Health,” “Omada,” the Omada logos, and other trade names, trademarks, or service marks of Omada
appearing in this prospectus are the property of Omada. Other trade names, trademarks, or service marks appearing in this prospectus are the property of their respective holders. We do not intend our use or display of other companies’ trade
names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Solely for convenience, trade names, trademarks, and service marks referred to in this prospectus appear without the ®, ™ and SM symbols, but those references are not intended to indicate, in any way,
that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, trademarks, and service marks.

Numerical figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown
as totals in various tables may not be arithmetic aggregations of the figures that precede them.

**We have not, and the
underwriters have not, authorized anyone to provide you any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you.
Neither we nor the underwriters take responsibility for, or provide any assurance as to the reliability of, any other information others may give you. This prospectus is an offer to sell only the shares offered hereby, and only under circumstances
and in jurisdictions where it is lawful to do so. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is
accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the shares of our common stock. Our business, financial condition, and results of operations may have changed since that date.**

---

##### [Table of Contents](#toc)

**For investors outside the United States:** We have not, and the
underwriters have not, done anything that would permit this offering or the possession or distribution of this prospectus or any free writing prospectus in connection with this offering in any jurisdiction where action for that purpose is required,
other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of
this prospectus outside the United States. See the section titled “Underwriters.”

**THROUGH AND
INCLUDING     , 2025 (THE 25TH DAY AFTER THE DATE OF THIS PROSPECTUS), ALL DEALERS THAT BUY, SELL, OR TRADE SHARES OF OUR COMMON STOCK, WHETHER OR NOT PARTICIPATING IN THIS OFFERING, MAY BE REQUIRED TO DELIVER A PROSPECTUS.
THIS DELIVERY REQUIREMENT IS IN ADDITION TO THE OBLIGATION OF DEALERS TO DELIVER A PROSPE

[... truncated ...]